Overview of AIM ImmunoTech's Pancreatic Cancer Program with Promising Follow-On Data Release| Thomas Equels, CEO, AIM ImmunoTech Inc. 00:10:00

Share On Facebook Share On Twitter

AIM ImmunoTech's CEO discusses the company's pancreatic cancer program and promising follow-on data from its flagship drug candidate trial.

Recent Videos